fda statement on compounded semaglutide 🚨 Moves to Permanently Shut Down GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA says 'no clinical need'

The program is designed to allow members to scale up and down in terms of intensity, tailoring the experience to their care needs

If you're in the smaller leagues, your best play is blood testing your patients

Legitimate policy conversations are needed about marketing practices, guardrails and consistent standards

It is hoped that ongoing trials like SUMMIT, which is investigating tirzepatide in participants with HFpEF and obesity, will provide more evidence on incretin-based medications in HFpEF

Some patients undergoing GLP-1 therapy experience a loss of facial volume as a result of rapid body composition changes a phenomenon sometimes referred to as "GLP-1 Face." Moderating the pace of change and eating a high-quality diet with plenty of protein may help reduce this risk